Toggle navigation
TWunroll
TWunroll
faq
Contact US
Sandip Patel MD
PatelOncology
KEYNOTE-158 study out in Lancet Oncology, Pembrolizumab for TMB>10- most data time date we have seen since FDA approval, key aspects include tumor types studiedhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30445-9/fu
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree